Anti EGFR (Epidermal Growth Factor Receptor) monoclonals bind to this receptor and inhibit its activation by its main ligands EGF, and also Transforming growth factor alpha (TGF alpha), avoiding the triggering of an oncogenic enzymatic cascade. Cetuximab is a chimeric monoclonal (part human, part murine); Panitumumab is "fully human".
